Chelation therapy doesn’t alter quality of life in heart attack patients
American Heart Association Late-Breaking Clinical Trial Report - Embargoed until 6:02pm PT/9:02pm ET
- Patients’ daily functioning and sense of mental wellbeing remained the same while receiving chelation therapy
- The weekly infusions, which remove metals from the blood, had no impact on patients’ ability to care for themselves or on their feelings of wellbeing or stress
- The new study examined more than 900 patients enrolled in the larger, overall TACT trial which found that chelation therapy reduced risk of some cardiac events.
LOS ANGELES, Nov. 4, 2012 — Chelation therapy didn’t change the ability to perform daily tasks or impact the emotional wellbeing of patients who previously suffered a heart attack, according to late-breaking clinical trial research presented at the American Heart Association’s Scientific Sessions 2012.
There was no impact on patient’s quality of life in this sub-study although the overall Trial to Assess Chelation Therapy (TACT) showed chelation therapy cut the risk of death, second heart attacks, stroke and the need for heart procedures among some patients who already suffered an earlier heart attack.
This quality-of-life study was a planned analysis of 911 randomly chosen patients from the overall trial of chelation therapy, an alternative treatment which uses weekly infusions to remove metals from the bloodstream.
“We didn’t see any effect on the quality of life of chelation therapy patients,” said Daniel B. Mark, M.D., M.P.H., lead author of the sub-study and professor of medicine, director of outcomes research at Duke University Medical Center and Duke Clinical Research Institute in Durham, N.C. “Patients weren’t any worse, but they weren’t any better.
One of the tools used to measure quality of life was the Duke Activity Status Index, DASI, to measure patients’ ability to complete daily tasks. The lowest score of 0 means the patient couldn’t do any chores associated with their own care such as feeding, toileting and dressing themselves. The highest score of 48 would be achieved by a professional athlete, Mark said.
At the beginning of the study, patients taking chelation therapy had a score of 24.6 and after two years it went up to 27.1. Those on placebo, dummy infusions that contained no medicine, had a baseline score of 23.5 that went up to 25.1. The small difference between chelation and placebo wasn’t significant enough to show a notable impact on how patients functioned in their daily lives.
The results were similar when researchers used the SF-36, the Short Form Health Survey, which assesses mental wellbeing or stress. After two years of chelation or placebo, patients reported similar scores.
“We thought it might make people feel better, but we didn’t see that consistently enough,” Mark said.
The main study examined the effectiveness of chelation therapy, which isn’t approved by the U.S. Food and Drug Administration to treat heart disease, but has long been used as an alternative treatment. It is approved, however as a prescription treatment for heavy metal poisoning such as mercury and lead poisoning.
Co-authors are Kevin J. Anstrom, Ph.D.; Robin Boineau, M.D.; Christine Goertz, D.C., Ph.D.; Theodore C. Rozema, M.D.; David Knight, M.S.; Nancy E Clapp-Channing, M.P.H.; Diane M Liu, C.C.R.P.; Richard L Nahin, Ph.D., M.P.H.; Yves Rosenberg, M.D., M.P.H.; Jeanne Drisko, M.D.; Kerry L. Lee, Ph.D.; and Gervasio A Lamas, M.D.
Disclosures are here http://newsroom.heart.org/pr/aha/document/DISCLOSURES.pdf
The National Heart, Lung, and Blood Institute funded the study.
Follow news from the American Heart Association’s Scientific Sessions 2012 via Twitter: @HeartNews.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
Note: The TACT Quality of Life presentation is 6:02 p.m. PT, Sunday, Nov. 4, in Hall G.
For Media Inquiries:
AHA News Media in Dallas: (214) 706-1396
AHA News Media Office, Nov. 3-7
at the Los Angeles Convention Center: (213) 743-6205
For Public Inquiries: (800) AHA-USA1 (242-8721)